Abstract
The search for an ideal anticoagulant has spanned decades and has taken several approaches to the identification of novel target molecules for preventing and treating thrombosis. In the group of anticoagulants acting through direct inhibition of coagulation factors, most research has focused on thrombin and factor Xa inhibitors. Attention has been drawn most recently to factor VIIa as a promising anticoagulation target, because of its role in complex with tissue factor, in initiating the coagulation cascade following blood vessel damage. Several reports suggest that inhibitors of the tissue factor/factor VIIa complex prevent thrombosis with a lower bleeding risk than other types of inhibitors. Accordingly, there is increasing interest in the generation of potent and selective small-molecule factor VIIa inhibitors that can be safely administered once or twice daily in an oral formulation with no need for routine coagulation monitoring. The emphasis of this review will be placed on recent advances in the development of the small-molecule inhibitors of factor VIIa complexed with tissue factor. The role of factor VIIa and tissue factor as initiators of the coagulation cascade following blood vessel damage is described, along with the structure of the active site of factor VIIa.
Keywords: Factor VIIa, tissue factor, tissue factor/factor VIIa inhibitors, anticoagulants, dual inhibitors
Current Pharmaceutical Design
Title: Recent Advances in the Discovery of Tissue Factor/Factor VIIa Inhibitors and Dual Inhibitors of Factor VIIa/Factor Xa
Volume: 11 Issue: 32
Author(s): A. Kranjc, D. Kikelj and L. Peterlin-Masic
Affiliation:
Keywords: Factor VIIa, tissue factor, tissue factor/factor VIIa inhibitors, anticoagulants, dual inhibitors
Abstract: The search for an ideal anticoagulant has spanned decades and has taken several approaches to the identification of novel target molecules for preventing and treating thrombosis. In the group of anticoagulants acting through direct inhibition of coagulation factors, most research has focused on thrombin and factor Xa inhibitors. Attention has been drawn most recently to factor VIIa as a promising anticoagulation target, because of its role in complex with tissue factor, in initiating the coagulation cascade following blood vessel damage. Several reports suggest that inhibitors of the tissue factor/factor VIIa complex prevent thrombosis with a lower bleeding risk than other types of inhibitors. Accordingly, there is increasing interest in the generation of potent and selective small-molecule factor VIIa inhibitors that can be safely administered once or twice daily in an oral formulation with no need for routine coagulation monitoring. The emphasis of this review will be placed on recent advances in the development of the small-molecule inhibitors of factor VIIa complexed with tissue factor. The role of factor VIIa and tissue factor as initiators of the coagulation cascade following blood vessel damage is described, along with the structure of the active site of factor VIIa.
Export Options
About this article
Cite this article as:
Kranjc A., Kikelj D. and Peterlin-Masic L., Recent Advances in the Discovery of Tissue Factor/Factor VIIa Inhibitors and Dual Inhibitors of Factor VIIa/Factor Xa, Current Pharmaceutical Design 2005; 11 (32) . https://dx.doi.org/10.2174/138161205774913282
DOI https://dx.doi.org/10.2174/138161205774913282 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preeclampsia and the Future Development of Cardiovascular Disease: A Review
Current Women`s Health Reviews Effects of Hypertension, Diabetes Mellitus, Obesity and Other Factors on Kidney Haemodynamics
Current Vascular Pharmacology Editorial [Hot topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Smoking-Related Cardiovascular Diseases (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Automated Percutaneous Lumbar Discectomy for Symptomatic C ontained Disc Herniation: An Updated Review
Current Medical Imaging Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View
Current Diabetes Reviews Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Uric Acid and Hypertension
Current Pharmaceutical Design Protein Regulators of Eicosanoid Synthesis: Role in Inflammation
Current Protein & Peptide Science History, Prevalence and Assessment of Limited Joint Mobility, from Stiff Hand Syndrome to Diabetic Foot Ulcer Prevention: A Narrative Review of the Literature
Current Diabetes Reviews Interrelationship between Chronic Kidney Disease and Risk of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Apolipoprotein B and Apolipopotein A-I in Vascular Risk Prediction-A Review
Current Pharmaceutical Design Editorial (Thematic Issue: G-protein Coupled Receptors in Vascular Biology: Implication in Health and Disease)
Current Vascular Pharmacology Gene Therapy for Ischemic Brain Diseases
Current Gene Therapy Increasing Neurogenesis with Fluoxetine, Simvastatin and Ascorbic Acid Leads to Functional Recovery in Ischemic Stroke
Recent Patents on Drug Delivery & Formulation New Approaches to Develop Anti-Staphylococcal Agents
Current Medicinal Chemistry - Anti-Infective Agents Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges
Current Drug Safety Fragment Library Screening and Lead Characterization Using SPR Biosensors
Current Topics in Medicinal Chemistry The Impact of Type 2 Diabetes on Women’s Health and Well-being During Their Reproductive Years: A Mixed-methods Systematic Review
Current Diabetes Reviews Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Determinants of the Resolution of Type 2 Diabetes After Bariatric Surgery
Vascular Disease Prevention (Discontinued)